Sacubitril/Valsartan in Daily Clinical Practice : Data From a Prospective Registry
Sacubitril/valsartan (SV) is a new therapy in heart failure with reduced ejection fraction. Our aim was to determine the efficacy and safety of this drug daily clinical practice. We performed a multicenter registry in 10 hospitals. All patients who started SV from October 2016 to March 2017 on an outpatient basis were included. A total of 427 patients started treatment with SV. Mean follow-up was 7.0 ± 0.1 months. Forty-nine patients (11.5%) discontinued SV, and 12 (2.8%) died. SV discontinuation was associated with higher cardiovascular (hazard ratio 13.22, 95% confidence interval, 6.71-15.73, P < 0.001) and all-cause mortality (hazard ratio 13.51, 95% confidence interval 3.22-56.13, P < 0.001). Symptomatic hypotension occurred in 71 patients (16.6%). Baseline N-terminal pro-B-type natriuretic peptide levels, functional class, and left ventricular ejection fraction improved at the end of follow-up in patients who continued with SV (all P values ≤0.001). This improvement was not significant in patients with SV discontinuation. SV has a good tolerability in patients from daily clinical practice. SV withdrawal in patients with heart failure and reduced ejection fraction was independently associated with increased all-cause mortality. Patients who continued with SV presented an improvement in functional class left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide levels.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Journal of cardiovascular pharmacology - 73(2019), 2 vom: 12. Feb., Seite 118-124 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vicent, Lourdes [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.02.2020 Date Revised 04.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/FJC.0000000000000641 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM291707327 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM291707327 | ||
| 003 | DE-627 | ||
| 005 | 20231225071451.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/FJC.0000000000000641 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0972.xml |
| 035 | |a (DE-627)NLM291707327 | ||
| 035 | |a (NLM)30540687 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vicent, Lourdes |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sacubitril/Valsartan in Daily Clinical Practice |b Data From a Prospective Registry |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.02.2020 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Sacubitril/valsartan (SV) is a new therapy in heart failure with reduced ejection fraction. Our aim was to determine the efficacy and safety of this drug daily clinical practice. We performed a multicenter registry in 10 hospitals. All patients who started SV from October 2016 to March 2017 on an outpatient basis were included. A total of 427 patients started treatment with SV. Mean follow-up was 7.0 ± 0.1 months. Forty-nine patients (11.5%) discontinued SV, and 12 (2.8%) died. SV discontinuation was associated with higher cardiovascular (hazard ratio 13.22, 95% confidence interval, 6.71-15.73, P < 0.001) and all-cause mortality (hazard ratio 13.51, 95% confidence interval 3.22-56.13, P < 0.001). Symptomatic hypotension occurred in 71 patients (16.6%). Baseline N-terminal pro-B-type natriuretic peptide levels, functional class, and left ventricular ejection fraction improved at the end of follow-up in patients who continued with SV (all P values ≤0.001). This improvement was not significant in patients with SV discontinuation. SV has a good tolerability in patients from daily clinical practice. SV withdrawal in patients with heart failure and reduced ejection fraction was independently associated with increased all-cause mortality. Patients who continued with SV presented an improvement in functional class left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide levels | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Aminobutyrates |2 NLM | |
| 650 | 7 | |a Angiotensin II Type 1 Receptor Blockers |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Biphenyl Compounds |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Tetrazoles |2 NLM | |
| 650 | 7 | |a pro-brain natriuretic peptide (1-76) |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 650 | 7 | |a Valsartan |2 NLM | |
| 650 | 7 | |a 80M03YXJ7I |2 NLM | |
| 650 | 7 | |a Neprilysin |2 NLM | |
| 650 | 7 | |a EC 3.4.24.11 |2 NLM | |
| 650 | 7 | |a sacubitril and valsartan sodium hydrate drug combination |2 NLM | |
| 650 | 7 | |a WB8FT61183 |2 NLM | |
| 700 | 1 | |a Esteban-Fernández, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Bueno, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a De-Juan, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Díez-Villanueva, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Iniesta, Ángel Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Ayesta, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a González-Saldívar, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Rojas-González, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Bover-Freire, Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Iglesias, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a García-Aguado, Marcos |e verfasserin |4 aut | |
| 700 | 1 | |a Perea-Egido, Jesús A |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Sellés, Manuel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiovascular pharmacology |d 1990 |g 73(2019), 2 vom: 12. Feb., Seite 118-124 |w (DE-627)NLM000951579 |x 1533-4023 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2019 |g number:2 |g day:12 |g month:02 |g pages:118-124 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/FJC.0000000000000641 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2019 |e 2 |b 12 |c 02 |h 118-124 | ||